

Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer

In this article (Clin Cancer Res 2015;21:670–4), which was published in the February 15, 2015, issue of *Clinical Cancer Research* (1), the authors' interpretation of the study in reference 22 has led to confusion among readers. In response, the authors have provided clarification. The sentence in the first paragraph on page 672 that reads "Gainor and colleagues reported the genotyping data from 1,683 patients with NSCLC finding 4 out of 75 ALK⁺ patients with KRAS mutations (22)" should now read "Gainor and colleagues reported the genotyping data from 1,683 patients with NSCLC finding 4 patients with KRAS mutations and abnormal ALK FISH patterns, however, with negative ALK expression by IHC in the 3 out of 4 samples with available tissue (22)." The authors regret this error.

Reference

1. Massarelli E, Papadimitrakopoulou V. Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer. Clin Cancer Res 2015;21:670–4.

Published online May 15, 2015.

doi: 10.1158/1078-0432.CCR-15-0482

©2015 American Association for Cancer Research.

Clinical Cancer Research

Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

Clin Cancer Res 2015;21:2412.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/10/2412>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/21/10/2412.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/10/2412>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.